Samuel James Lynskey

Dr. Samuel James Lynskey

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in British Journal of Radiology
Verified
Journal Article
Closed access
SLSamuel James Lynskey
Samuel James Lynskey
MPMarcus J Pianta
Marcus J Pianta
Objective:The purpose of this study was to characterize the MRI and thallium-201 (201TI) scintigraphy attributes of pigmented villonodular synovitis (PVNS) and giant cell tumours of tendon sheaths (GCTTS). The epidemiology of these uncommon lesions was also assessed and less commonly encountered pathology reported on including multifocality, necrosis and concurrent malignancy.Methods:A retrospective single centre review of MRI and 201TI scintigraphy findings for 83 surgically proven or biopsy-proven consecutive cases of PVNS was undertaken. Radiological findings including lesion size, 201TI uptake (as a marker of metabolic activity), location, extent and patient demographics were correlated with biopsy and surgical specimen histology. Typical appearances are described, as well as less common imaging manifestations. The study period encompassed all patients presenting or referred to a tertiary bone and soft-tissue tumour referral centre with PVNS or GCTTS between 1 January 2007 and the 1 December 2013.Resu...

1 February 2021 in The Surgeon
Verified
Journal Article
Closed access
SLSamuel James Lynskey
Samuel James Lynskey
FLFerraby Ling
Ferraby Ling
AGAlana M. Greenberg
Alana M. Greenberg
JPJahan C. Penny-Dimri
Jahan C. Penny-Dimri
ASAlasdair G. Sutherland
Alasdair G. Sutherland

8 March 2023 in Life
Verified
Journal Article
Open access
PDF file
SLSamuel James Lynskey
Samuel James Lynskey
MMMarc Julian Macaluso
Marc Julian Macaluso
SGStephen Gill
Stephen Gill
SMSean L. McGee
Sean L. McGee
RPRichard S Page
Richard S Page
Development of OA (OA) is multifactorial and is strongly associated with risk factors such as aging, trauma, metabolic disorders, and obesity. Metabolic Syndrome (MetS)-associated OA, collectively coined MetS-OA, is an increasingly recognized entity in which metabolic disorders and low-grade inflammation play a key mechanistic role in the disruption of joint homeostasis and cartilage degradation. Although there have been enormous efforts to discover biomarkers of MetS and OA, studies investigating a pathophysiological link between MetS and OA are relatively limited, and no serum blood marker has proved diagnostic so far. OA biomarkers that are necessary to discriminate and diagnose early disease remain to be elicited, explained in part by limited prospective studies, and therefore limited tools available to utilize in any prognostic capacity. Biomarker validation projects have been established by the Biomarker Consortium to determine biochemical markers demonstrating predictive validity for knee OA. Given that the metabolic constituents of MetS are treatable to varying extents, it stands to reason that treating these, and monitoring such treatment, may help to mitigate deleterious links with OA development. This narrative review will describe the current state of biomarker identification and utility in OA associated with MetS. We discuss the pathophysiological mechanisms of disease according to constituent pathologies of MetS and how identification of biomarkers may guide future investigation of novel targets.

28 July 2025 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Open access
SLSamuel James Lynskey
Samuel James Lynskey
CMCooper Moody
Cooper Moody
MZMark Ziemann
Mark Ziemann
SGStephen D. Gill
Stephen D. Gill
SMSean L. McGee
Sean L. McGee
RPRichard S Page
Richard S Page
Rotator cuff tears are a leading cause of shoulder pain and dysfunction, with variable healing after rotator cuff repair. Predicting tendon healing remains challenging, with failure rates reaching 21% at 2 years. This study employs transcriptomic analysis to identify gene pathways associated with tendon healing, with clinical and radiological correlation at 2 years postoperatively. A prospective multicenter laboratory-based and clinical study of 25 patients undergoing arthroscopic rotator cuff repair was conducted. Intraoperative biopsies were taken from the torn rotator cuff tendon, RNA sequencing was performed, and differential gene expression was analyzed using DESeq2. Functional pathway enrichment was assessed via Reactome and the mitch Bioconductor package. Patient-reported outcome measures, including Oxford Shoulder Score, Quick Disabilities of the Arm, Shoulder and Hand score, and EuroQol Visual Analog Scale, were collected at baseline, 3 months, 12 months, and 2 years. At 2 years, tendons were classified as intact or torn based on standardized gray scale ultrasound, interpreted by experienced musculoskeletal sonographers. Intact tendons showed no visible discontinuity, cleft, or delamination. Both intact (67%) and torn groups (33%) showed significant patient-reported outcome measure improvements, with no statistically significant differences between groups. The torn group experienced an early decline in EuroQol Visual Analog Scale scores, recovering by 12 months and stabilizing by 2 years, while the intact group maintained stable scores. Transcriptomic analysis revealed distinct differences: intact tendons showed increased activity in DNA repair and extracellular matrix (ECM) stabilization pathways, alongside reduced inflammation and enhanced metabolism. In contrast, torn tendons exhibited ongoing inflammation and impaired ECM remodeling. Rotator cuff healing involves suppression of inflammation and activation of reparative transcriptional, metabolic, and ECM pathways. Nonhealing tendons display persistent stress, disrupted fibrinolysis, and epigenetic dysregulation. Key molecular signals, including forkhead box O, histone demethylases, zinc transport, matrix metalloproteinases, and SERPINE1, represent promising biomarker candidates for risk stratification and targeted therapy. While transcriptomics remains investigational, these findings support a precision surgery approach, with future integration of molecular diagnostics to personalize treatment and reduce retear risk.

Verified
Journal Article
Open access
PDF file
SLSamuel James Lynskey
Samuel James Lynskey
ZLZihui Ling
Zihui Ling
MZMark Ziemann
Mark Ziemann
SGStephen Gill
Stephen Gill
SMSean L. McGee
Sean L. McGee
RPRichard S Page
Richard S Page
Metabolic syndrome (MetS) associated with Osteoarthritis (OA) is an increasingly recognised entity. Whilst the degenerative pattern in cuff-tear arthropathy (CTA) has been well documented, the biological processes behind primary shoulder OA and CTA remain less understood. This study investigates transcriptomic differences in these conditions, alongside the impact of MetS in patients undergoing total shoulder replacement. In a multi-centre study, 20 OA patients undergoing total shoulder replacement were included based on specific treatment indications for OA and cuff-tear arthropathy as well as 25 patients undergoing rotator cuff repair (RCR) as a comparator group. Tissues from subchondral bone, capsule (OA and RCR), and synovium were biopsied, and RNA sequencing was performed using Illumina platforms. Differential gene expression was conducted using DESeq2, adjusting for demographic factors, followed by pathway enrichment using the mitch package. Gene expressions in CTA and primary OA was differentially affected. CTA showed mitochondrial dysfunction, GATD3A downregulation, and increased cartilage degradation, while primary OA was marked by upregulated inflammatory and catabolic pathways. The effect of MetS on these pathologies was further shown. MetS further disrupted WNT/β-catenin signalling in CTA, and in OA. Genes such as ACAN, PANX3, CLU, and VAT1L were upregulated, highlighting potential biomarkers for early OA detection. This transcriptomic analysis reveals key differences between end-stage CTA and primary glenohumeral OA. CTA shows heightened metabolic/protein synthesis activity with less immune-driven inflammation. Under MetS, mitochondrial dysfunction (including GATD3A downregulation) and altered Wnt/β-catenin signalling intensify cartilage and bone damage. In contrast, primary OA features strong complement activation, inflammatory gene expression, and collagen remodelling. MetS worsens both conditions via oxidative stress, advanced glycation end products, and ECM disruption—particularly, increased CS/DS degradation. These distinctions support targeted treatments, from antioxidants and Wnt modulators to aggrecanase inhibitors or clusterin augmentation. Addressing specific molecular disruptions, especially those amplified by MetS, may preserve shoulder function, delay surgical intervention, and improve long-term patient outcomes.

28 November 2023 in Research Square
Verified
Preprint
Open access
PDF file
SLSamuel James Lynskey
Samuel James Lynskey
SGStephen D. Gill
Stephen D. Gill
SMSean L. McGee
Sean L. McGee
MZMark Ziemann
Mark Ziemann
RPRichard S. Page
Richard S. Page
Osteoarthritis (OA) is a disease of the synovial joint complex. A limited number of studies have directly investigated transcriptional changes in shoulder OA. Further, gene expression patterns of periarticular tissues in OA have not been thoroughly investigated. This prospective case control series details transcriptomic expression of shoulder OA by analysing periarticular tissues in patients undergoing shoulder replacement for OA as correlated with a validated patient reported outcome measure of worsening shoulder function, a higher (clinically worsening) QuickDASH score. We then compared transcriptomic expression profiles in capsular tissue biopsies from the OA group as compared to patients undergoing shoulder stabilisation for recurrent instability (the control group). Results indicated that top ranked genes associated with increasing QuickDASH score across all tissues involved inflammation and response to stress. These included interleukins, chemokines, complement components, nuclear response factors and immediate early response genes. Some of these genes were upregulated, and some downregulated, suggestive of a state of flux between inflammatory and anti-inflammatory signalling pathways. We have also described gene expression pathways in shoulder OA not previously identified in hip and knee OA, as well as novel genes involved in shoulder OA.